Executive Summary: The Dissolution of the Détente The pharmaceutical ecosystem currently faces a structural realignment of unprecedented magnitude. For decades, […]

Beyond the Legal Formality: Why Patent Strategy is a Core Business Imperative For too long, patent strategy has been relegated

The traditional American pharmaceutical supply chain operates as a fortress of opacity, defended by a complex triad of pharmacy benefit

The enactment of the Inflation Reduction Act (IRA) of 2022 represents a paradigmatic shift in the United States biopharmaceutical landscape,

The global pharmaceutical industry reached a valuation of $1.6 trillion in 2023.1 Projections show this market will hit $2.35 trillion

The global pharmaceutical landscape is currently navigating a period of unprecedented fiscal exposure, characterized by a looming “super-cliff” of patent

The pharmaceutical industry has moved away from the traditional model of innovation where a single patent protects a drug for

The pharmaceutical industry in 2026 stands at a critical juncture where the traditional “patent cliff”—the once-dreaded moment when a blockbuster

The Strategic Bridge: Unpacking the 505(b)(2) Paradox A “Hybrid” Revolution: Defining the 505(b)(2) In the complex and resource-intensive world of